VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
India has taken the lead in recognising NAFLD as a major non-communicable disease
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Pfizer's decision is based on the totality of clinical data
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Subscribe To Our Newsletter & Stay Updated
